Otsuka Holdings Co., Ltd. (OTSKY)
USD 27.55
(-0.4%)
USD 27.55
(-0.4%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 139.61 Billion JPY | 32.49% |
| 2022 | 220.53 Billion JPY | 42.75% |
| 2021 | 154.49 Billion JPY | -22.2% |
| 2020 | 198.58 Billion JPY | 12.46% |
| 2019 | 176.58 Billion JPY | 63.05% |
| 2018 | 108.3 Billion JPY | 3.96% |
| 2017 | 104.18 Billion JPY | 3.0% |
| 2016 | 101.14 Billion JPY | -33.39% |
| 2015 | 151.83 Billion JPY | -27.61% |
| 2014 | 209.74 Billion JPY | 23.62% |
| 2013 | 169.66 Billion JPY | 14.13% |
| 2012 | 148.66 Billion JPY | 26.52% |
| 2011 | 117.5 Billion JPY | 19.31% |
| 2010 | 98.48 Billion JPY | 7.61% |
| 2009 | 91.52 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 113.47 Billion JPY | 39.09% |
| 2024 Q1 | 81.57 Billion JPY | 60.49% |
| 2023 Q4 | 50.83 Billion JPY | -29.36% |
| 2023 Q1 | 76.77 Billion JPY | 116.43% |
| 2023 Q2 | 53.91 Billion JPY | -29.78% |
| 2023 Q3 | 71.95 Billion JPY | 33.48% |
| 2023 FY | 292.19 Billion JPY | 32.49% |
| 2022 Q3 | 47.7 Billion JPY | -25.4% |
| 2022 Q4 | 35.47 Billion JPY | -25.63% |
| 2022 FY | 220.53 Billion JPY | 42.75% |
| 2022 Q1 | 55.85 Billion JPY | 1637.35% |
| 2022 Q2 | 63.94 Billion JPY | 14.49% |
| 2021 FY | 154.49 Billion JPY | -22.2% |
| 2021 Q3 | 46.96 Billion JPY | -23.11% |
| 2021 Q4 | -3.63 Billion JPY | -107.74% |
| 2021 Q2 | 61.07 Billion JPY | 21.93% |
| 2021 Q1 | 50.09 Billion JPY | 86.31% |
| 2020 Q3 | 53.68 Billion JPY | -16.2% |
| 2020 Q2 | 64.06 Billion JPY | 18.75% |
| 2020 FY | 198.58 Billion JPY | 12.46% |
| 2020 Q1 | 53.94 Billion JPY | 159.92% |
| 2020 Q4 | 26.88 Billion JPY | -49.92% |
| 2019 Q3 | 59.3 Billion JPY | -9.21% |
| 2019 FY | 176.58 Billion JPY | 63.05% |
| 2019 Q4 | 20.75 Billion JPY | -65.0% |
| 2019 Q2 | 65.32 Billion JPY | 109.34% |
| 2019 Q1 | 31.2 Billion JPY | 170.06% |
| 2018 Q3 | 18.44 Billion JPY | -57.64% |
| 2018 Q2 | 43.53 Billion JPY | 25.22% |
| 2018 Q4 | 11.55 Billion JPY | -37.35% |
| 2018 FY | 108.3 Billion JPY | 3.96% |
| 2018 Q1 | 34.76 Billion JPY | 274.02% |
| 2017 Q3 | 45.37 Billion JPY | 134.66% |
| 2017 FY | 104.18 Billion JPY | 3.0% |
| 2017 Q4 | 9.29 Billion JPY | -79.51% |
| 2017 Q2 | 19.33 Billion JPY | -35.9% |
| 2017 Q1 | 30.16 Billion JPY | 342.62% |
| 2016 Q2 | 48.29 Billion JPY | 80.48% |
| 2016 Q4 | -12.43 Billion JPY | -127.12% |
| 2016 FY | 101.14 Billion JPY | -33.39% |
| 2016 Q3 | 45.85 Billion JPY | -5.07% |
| 2016 Q1 | 26.76 Billion JPY | 460.11% |
| 2015 FY | 151.83 Billion JPY | -27.61% |
| 2015 Q4 | 4.77 Billion JPY | -89.12% |
| 2015 Q3 | 43.9 Billion JPY | -14.88% |
| 2015 Q2 | 51.57 Billion JPY | -0.03% |
| 2015 Q1 | 51.58 Billion JPY | 0.0% |
| 2014 Q2 | 65.56 Billion JPY | 396.29% |
| 2014 Q1 | 13.21 Billion JPY | -82.09% |
| 2014 FY | 209.74 Billion JPY | 23.62% |
| 2014 Q3 | 71.08 Billion JPY | 8.42% |
| 2013 Q1 | 38.24 Billion JPY | 0.7% |
| 2013 Q2 | 50.54 Billion JPY | 32.15% |
| 2013 Q4 | 73.77 Billion JPY | 20.59% |
| 2013 Q3 | 61.17 Billion JPY | 21.04% |
| 2013 FY | 169.66 Billion JPY | 14.13% |
| 2012 Q4 | 37.97 Billion JPY | -14.8% |
| 2012 FY | 148.66 Billion JPY | 26.52% |
| 2012 Q3 | 44.57 Billion JPY | -8.77% |
| 2012 Q2 | 48.86 Billion JPY | 214.24% |
| 2012 Q1 | 15.54 Billion JPY | -66.73% |
| 2011 Q3 | 40.02 Billion JPY | -13.67% |
| 2011 Q4 | 46.73 Billion JPY | 16.77% |
| 2011 Q2 | 46.35 Billion JPY | 126.84% |
| 2011 Q1 | 20.43 Billion JPY | -24.86% |
| 2011 FY | 117.5 Billion JPY | 19.31% |
| 2010 Q4 | 27.19 Billion JPY | -20.55% |
| 2010 Q1 | 7.54 Billion JPY | -75.35% |
| 2010 Q2 | 35.63 Billion JPY | 372.34% |
| 2010 Q3 | 34.23 Billion JPY | -3.95% |
| 2010 FY | 98.48 Billion JPY | 7.61% |
| 2009 Q2 | 25 Billion JPY | 0.0% |
| 2009 Q4 | 30.61 Billion JPY | -13.32% |
| 2009 Q3 | 35.31 Billion JPY | 41.23% |
| 2009 FY | 91.52 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | -1604.04% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | -709.72% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | -1889.906% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 351484.275% |
| Novartis AG | 9.76 Billion USD | -1329.133% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 96.149% |